Multimodal Analgesic Formulation for Reduced PONV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current postoperative pain management modalities, particularly opioids, are incomplete and often cause significant adverse effects, morbidity, and mortality, with a high incidence of postoperative nausea and vomiting (PONV) that persists beyond 24 hours, contributing to the opioid crisis and impacting patient recovery.
Innovation Solution
A multimodal opioid-free analgesic formulation comprising Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, administered in a synergistic combination to provide prolonged analgesia with minimal toxicity and reduced side effects, effectively reducing PONV and enhancing pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If unimodal opioid analgesics are used for postoperative pain management, then pain relief is provided, but postoperative nausea and vomiting (PONV) occurs at high incidence
Solution Approach 1:
The patent divides the single opioid analgesic approach into multiple separate analgesic agents (local anesthetic, NMDA receptor antagonist, and COX inhibitor) that work through different mechanisms. This segmentation allows each component to contribute to pain relief while minimizing the PONV side effects associated with opioids.
Solution Approach 2:
The patent creates a composite analgesic formulation combining three distinct drug classes (local anesthetic, NMDA receptor antagonist, and COX inhibitor) into a single multimodal therapy. This composite approach provides synergistic pain relief while avoiding the harmful PONV effects of unimodal opioid use.
2Object-affected harmful factors
If opioids are used for postoperative pain management, then pain relief is achieved, but adverse effects and mortality increase
Solution Approach 1:
The patent segments the analgesic approach into multiple non-opioid mechanisms (local anesthetic blockade, NMDA receptor antagonism, and COX inhibition), eliminating opioid exposure and its associated adverse effects and mortality risks while maintaining effective pain relief.
Solution Approach 2:
The patent formulates a composite of three non-opioid analgesic agents that work synergistically to provide reliable pain relief without the harmful adverse effects and mortality associated with opioid use.
3Object-affected harmful factors
If current postoperative pain management modalities are used, then pain treatment is provided, but patient recovery is impacted
Solution Approach 1:
The patent segments pain management into multiple targeted mechanisms that address different aspects of postoperative pain (peripheral nerve blockade, central sensitization, and inflammation) without the recovery-compromising side effects of opioids, enabling faster patient recovery.
Solution Approach 2:
The patent develops a composite analgesic formulation that provides comprehensive pain management while promoting patient recovery by avoiding opioid-related complications.
Data Source
AI summary
A multimodal antiemetic anesthetic/analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free/sparing anesthetic/analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics/analgesics. The formulation is administered to a mammal in need of anesthesia/analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.